Literature DB >> 19808224

Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid.

Aiwu Lin1, Jiaqi Qian, Xiaomei Li, Xueqing Yu, Wenhu Liu, Yang Sun, Nan Chen, Changlin Mei.   

Abstract

BACKGROUND AND OBJECTIVES: While peritoneal dialysis with icodextrin is commonly used in patients with poor peritoneal membrane characteristics, the data on the usefulness of this solution in patients with lower transport characteristics are limited. The study was designed to compare icodextrin to glucose in Chinese prevalent peritoneal dialysis patients of different peritoneal transport characteristics (PET) categories. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a randomized, double-blind, perspective control study. Stable prevalent continuous ambulatory peritoneal dialysis (CAPD) patients were randomized to either 7.5% icodextrin (ICO) or 2.5% glucose (GLU) solution for 4 wk. Peritoneal membrane function was measured to define PET category in baseline. Creatinine clearance (Ccr), urea nitrogen clearance (C(BUN)), ultrafiltration (UF) during the long night dwell, dialysate, and metabolic biomarkers were measured at baseline, 2, and 4 wk. UF, Ccr, and C(BUN) were compared among different PET categories.
RESULTS: A total of 201 CAPD patients were enrolled in the study. There were no baseline differences between the groups. Following 2 and 4 wk of therapy, Ccr, C(BUN,) and UF were all significantly higher in the ICO versus the GLU group. Additionally, switching to ICO resulted in a significant increase in UF in high, high-average, and low-average transporters as compared with baseline. The extent of increased UF was more obvious in higher transporters. Blood cholesterol level in the ICO group decreased significantly than that in the GLU group.
CONCLUSION: Compared with glucose-based solution, 7.5% icodextrin significantly improved UF and small solute clearance, even in patients with low-average peritoneal transport.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808224      PMCID: PMC2774964          DOI: 10.2215/CJN.02950509

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  19 in total

Review 1.  Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis.

Authors:  S Mujais; K Nolph; R Gokal; P Blake; J Burkart; G Coles; Y Kawaguchi; H Kawanishi; S Korbet; R Krediet; B Lindholm; D Oreopoulos; B Rippe; R Selgas
Journal:  Perit Dial Int       Date:  2000       Impact factor: 1.756

Review 2.  Metabolic and laboratory effects of icodextrin.

Authors:  Ram Gokal; James Moberly; Bengt Lindholm; Salim Mujais
Journal:  Kidney Int Suppl       Date:  2002-10       Impact factor: 10.545

3.  Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival.

Authors:  M E Wilkie; M J Plant; L Edwards; C B Brown
Journal:  Perit Dial Int       Date:  1997 Jan-Feb       Impact factor: 1.756

4.  A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis.

Authors:  Marsha Wolfson; Beth Piraino; Richard J Hamburger; A Ross Morton
Journal:  Am J Kidney Dis       Date:  2002-11       Impact factor: 8.860

5.  Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis.

Authors:  G Woodrow; G Stables; B Oldroyd; J Gibson; J H Turney; A M Brownjohn
Journal:  Nephrol Dial Transplant       Date:  1999-06       Impact factor: 5.992

6.  The relationship between ultrafiltrate volume with icodextrin and peritoneal transport pattern according to the peritoneal equilibration test.

Authors:  Maria Regina Araújo Teixeira; Roberto Flávio Silva Pecoits-Filho; João Egidio Romão Junior; Emil Sabbaga; Marcello Machado Marcondes; Hugo Abensur
Journal:  Perit Dial Int       Date:  2002 Mar-Apr       Impact factor: 1.756

7.  Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration.

Authors:  Fredric Finkelstein; Helen Healy; Ali Abu-Alfa; Suhail Ahmad; Fiona Brown; Todd Gehr; Kevin Nash; Michael Sorkin; Salim Mujais
Journal:  J Am Soc Nephrol       Date:  2004-12-29       Impact factor: 10.121

8.  Comparison of peritoneal dialysis practice patterns and outcomes between a Canadian and a Chinese centre.

Authors:  Wei Fang; Jiaqi Qian; Aiwu Lin; Fadel Rowaie; Zhaohui Ni; Qiang Yao; Joanne M Bargman; Dimitrios G Oreopoulos
Journal:  Nephrol Dial Transplant       Date:  2008-09-12       Impact factor: 5.992

9.  Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group.

Authors:  D N Churchill; K E Thorpe; K D Nolph; P R Keshaviah; D G Oreopoulos; D Pagé
Journal:  J Am Soc Nephrol       Date:  1998-07       Impact factor: 10.121

10.  Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload.

Authors:  D W Johnson; M Arndt; A O'Shea; R Watt; J Hamilton; K Vincent
Journal:  BMC Nephrol       Date:  2001-12-03       Impact factor: 2.388

View more
  14 in total

1.  Should glucose-sparing prescriptions be expected to reduce the cardiovascular risk of peritoneal dialysis patients?

Authors:  Rajnish Mehrotra; Ian H de Boer
Journal:  J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 10.121

2.  Peritoneal residual volume induces variability of ultrafiltration with icodextrin.

Authors:  Alp Akonur; Clifford J Holmes; John K Leypoldt
Journal:  Perit Dial Int       Date:  2013-10-31       Impact factor: 1.756

3.  The solution to better preservation of the peritoneal membrane still lies hidden in the solution.

Authors:  Dirk G Struijk
Journal:  Perit Dial Int       Date:  2015 Mar-Apr       Impact factor: 1.756

Review 4.  Strategies for preventing peritoneal fibrosis in peritoneal dialysis patients: new insights based on peritoneal inflammation and angiogenesis.

Authors:  Zhen Zhang; Na Jiang; Zhaohui Ni
Journal:  Front Med       Date:  2017-08-08       Impact factor: 4.592

Review 5.  An update on peritoneal dialysis solutions.

Authors:  Elvia García-López; Bengt Lindholm; Simon Davies
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

6.  Icodextrin Simplifies PD Therapy by Equalizing UF and Sodium Removal Among Patient Transport Types During Long Dwells: A Modeling Study.

Authors:  Alp Akonur; James Sloand; Ira Davis; John Leypoldt
Journal:  Perit Dial Int       Date:  2014-09-02       Impact factor: 1.756

7.  Peritonitis is still an important factor for withdrawal from peritoneal dialysis therapy in the Tokai area of Japan.

Authors:  Masashi Mizuno; Yasuhiko Ito; Akio Tanaka; Yasuhiro Suzuki; Hideki Hiramatsu; Midoriko Watanabe; Yoshikazu Tsuruta; Teppei Matsuoka; Isao Ito; Hiroshi Tamai; Hirotake Kasuga; Hideaki Shimizu; Hisashi Kurata; Daijo Inaguma; Takeyuki Hiramatsu; Masanobu Horie; Tomohiko Naruse; Shoichi Maruyama; Enyu Imai; Yukio Yuzawa; Seiichi Matsuo
Journal:  Clin Exp Nephrol       Date:  2011-06-21       Impact factor: 2.801

8.  Predicting the Peritoneal Absorption of Icodextrin in Rats and Humans Including the Effect of α-Amylase Activity in Dialysate.

Authors:  Alp Akonur; Clifford J Holmes; John K Leypoldt
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

Review 9.  [Peritoneal dialysis from the beginnings up to today: which developments of the last decades were important?].

Authors:  Andreas Vychytil
Journal:  Wien Med Wochenschr       Date:  2013-04-17

10.  Biocompatible dialysis fluids for peritoneal dialysis.

Authors:  Htay Htay; David W Johnson; Kathryn J Wiggins; Sunil V Badve; Jonathan C Craig; Giovanni Fm Strippoli; Yeoungjee Cho
Journal:  Cochrane Database Syst Rev       Date:  2018-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.